Patent ID: 8664382

Claim:
Pharmaceutical compositions comprising at least a metal phthalocyanine analogue of formula (I) wherein n is 0, 1 or 2; M is chosen in the group consisting of Zn, Si(OR 3 ) 2 and AlOR 3 wherein R 3 is chosen in the group consisting of H and C 1-15 alkyl; R is chosen from H and W, wherein W is represented by the group (X) p R 4 , wherein: X is chosen in the group consisting of O, S, —NR 7 and —CH 2 —; and R 4 is where: Y is chosen in the group consisting of C 1-10 alkyl and phenyl, or it forms with the Z group, to which it is bound, a saturated or unsaturated heterocycle selected from the group consisting of: morpholine, piperidine, pyridine, pyrimidine, piperazine, pyrrolidine, pyrroline, imidazole, julolidine (2,3,6,7-tetrahydro-1H,5H-pirido[3,2,1-Ij] quinoline; Z is chosen in the group consisting of —N, —CH 2 N and —CONHCH 2 CH 2 N; R 5 and R 6 , equal or different from one another, are chosen in the group consisting of C 1-15 alkyl and phenyl, or form with the Z group, to which they are bound, a saturated or unsaturated heterocycle selected from the group consisting of: morpholine, piperidine, pyridine, pyrimidine, piperazine, pyrrolidine, pyrroline, imidazole, julolidine (2,3,6,7-tetrahydro-1H,5H-pirido[3,2,1-Ij] quinoline; R 7 and R 8 , equal or different from one another, are chosen in the group consisting of H and C 1-15 alkyl; m, n, p, s, t and u, independently from one another, are 0 or 1; and v is an integer comprised between 1 and 3; R 1 and R 2 , same or different from each other, are chosen from H, W and K, wherein W is as defined above, and K is selected from the group consisting of —COOH, —SH, —OH, —NH 2 , —COCH 2 Br, SO 2 Cl, maleimide, hydrazide, phenol, imidate, and biotine, bound to the phthalocyanine nucleus, either directly or through an aliphatic moiety which acts as a spacer; with the proviso that: when n=0: a) R 1 ═R 2 ═W in the position 1, 4 or 2,3; or b) R 1 ═H and R 2 ═W in the position 1 or 2; or c) R 1 ═H and R 2 ═K in the position 1 or 2; when n=1: d) R 1 ═H, and R═R 2 ═W; or e) R 1 ═H, R═W and R 2 ═K; in both cases d) and e) R is in the positions 8(11), 15(18), 22(25), or 9(10), 16(17), 23(24); and R 2 is in the position 1(4) or 2(3); when n=2: f) R═R 1 ═R 2 ═W; or g) R 1 ═H, R═W and R 2 ═K; in both cases f) and g) R is in the positions 8,11,15,18,22,25, or 9,10,16,17,23,24; and in the case f) R 1 and R 2 are in the positions 1, 4 or 2,3; whereas in the case g) R 2 is in the position 1(4) or 2(3); in combination with at least a metal chelating agent.